File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus

TitleSerum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus
Authors
KeywordsInterleukin-33
Soluble ST2
Systemic lupus erythematosus disease activity index
T helper 2 immune response
Issue Date2009
PublisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
Citation
Rheumatology, 2009, v. 49 n. 3, p. 520-527 How to Cite?
Abstract
Objective. IL-33 has recently been found to be the specific ligand of ST2, an IL-1 receptor family member that is selectively expressed in Th2 cells and mediates Th2 response. This study aims to measure the serum levels of soluble ST2 (sST2) and IL-33 in patients with SLE and to examine their association with disease activity. Methods. Seventy SLE patients were evaluated for disease activity, determined by SLEDAI, levels of anti-dsDNA antibody, C3 and C4. Fifty-seven patients were evaluated longitudinally on a second occasion. IL-33 and sST2 were measured by sandwich ELISA in the 127 SLE serum samples and compared with 28 age-and sex-matched healthy controls. Results. Serum sST2 level was significantly higher in active SLE patients [0.51 (0.18) ng/ml] compared with inactive patients [0.42 (0.08) ng/ml] (P = 0.006) and normal controls [0.36 (0.13) ng/ml] (P<0.001). sST2 level correlated significantly with SLEDAI, anti-dsDNA antibody and prednisolone dosage, and negatively with C3. Linear regression analysis showed that serum sST2 level was an independent predictive factor for modified SLEDAI, excluding anti-dsDNA and complement score after controlling for age, sex, glomerular filtration rate and prednisolone dosage (regression coefficient: 8.5; 95% CI 2.6, 14.3) (P = 0.005). Serum sST2 level was sensitive to change in disease activity longitudinally, with an effect size of 0.29. Elevated serum IL-33 was comparable in frequency (4.3 vs 7.1%; P = 0.62) and levels (P = 0.53) between SLE patients and controls. Conclusions. Elevated serum sST2 level in SLE patients was found to correlate with disease activity and was sensitive to change, suggesting a potential role as a surrogate marker of disease activity. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Persistent Identifierhttp://hdl.handle.net/10722/163300
ISSN
2013 Impact Factor: 4.435
ISI Accession Number ID
References

 

Author Affiliations
  1. The University of Hong Kong
  2. University of Glasgow
  3. Imperial College London
  4. Queen Mary Hospital Hong Kong
DC FieldValueLanguage
dc.contributor.authorMok, MYen_HK
dc.contributor.authorHuang, FPen_HK
dc.contributor.authorIp, WKen_HK
dc.contributor.authorLo, Yen_HK
dc.contributor.authorWong, FYen_HK
dc.contributor.authorChan, EYTen_HK
dc.contributor.authorLam, KFen_HK
dc.contributor.authorXu, Den_HK
dc.date.accessioned2012-09-05T05:29:50Z-
dc.date.available2012-09-05T05:29:50Z-
dc.date.issued2009en_HK
dc.identifier.citationRheumatology, 2009, v. 49 n. 3, p. 520-527en_HK
dc.identifier.issn1462-0324en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163300-
dc.description.abstractObjective. IL-33 has recently been found to be the specific ligand of ST2, an IL-1 receptor family member that is selectively expressed in Th2 cells and mediates Th2 response. This study aims to measure the serum levels of soluble ST2 (sST2) and IL-33 in patients with SLE and to examine their association with disease activity. Methods. Seventy SLE patients were evaluated for disease activity, determined by SLEDAI, levels of anti-dsDNA antibody, C3 and C4. Fifty-seven patients were evaluated longitudinally on a second occasion. IL-33 and sST2 were measured by sandwich ELISA in the 127 SLE serum samples and compared with 28 age-and sex-matched healthy controls. Results. Serum sST2 level was significantly higher in active SLE patients [0.51 (0.18) ng/ml] compared with inactive patients [0.42 (0.08) ng/ml] (P = 0.006) and normal controls [0.36 (0.13) ng/ml] (P<0.001). sST2 level correlated significantly with SLEDAI, anti-dsDNA antibody and prednisolone dosage, and negatively with C3. Linear regression analysis showed that serum sST2 level was an independent predictive factor for modified SLEDAI, excluding anti-dsDNA and complement score after controlling for age, sex, glomerular filtration rate and prednisolone dosage (regression coefficient: 8.5; 95% CI 2.6, 14.3) (P = 0.005). Serum sST2 level was sensitive to change in disease activity longitudinally, with an effect size of 0.29. Elevated serum IL-33 was comparable in frequency (4.3 vs 7.1%; P = 0.62) and levels (P = 0.53) between SLE patients and controls. Conclusions. Elevated serum sST2 level in SLE patients was found to correlate with disease activity and was sensitive to change, suggesting a potential role as a surrogate marker of disease activity. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology.en_HK
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/en_HK
dc.relation.ispartofRheumatologyen_HK
dc.subjectInterleukin-33en_HK
dc.subjectSoluble ST2en_HK
dc.subjectSystemic lupus erythematosus disease activity indexen_HK
dc.subjectT helper 2 immune responseen_HK
dc.subject.meshAdulten_US
dc.subject.meshAntibodies, Antinuclear - Blooden_US
dc.subject.meshBiological Markers - Blooden_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshEpidemiologic Methodsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlucocorticoids - Administration & Dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive Agents - Administration & Dosageen_US
dc.subject.meshInterleukins - Blooden_US
dc.subject.meshLupus Erythematosus, Systemic - Drug Therapy - Immunologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisolone - Administration & Dosageen_US
dc.subject.meshReceptors, Cell Surface - Blooden_US
dc.titleSerum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosusen_HK
dc.typeArticleen_HK
dc.identifier.emailMok, MY: temy@hkucc.hku.hken_HK
dc.identifier.emailLam, KF: hrntlkf@hkucc.hku.hken_HK
dc.identifier.authorityMok, MY=rp00490en_HK
dc.identifier.authorityLam, KF=rp00718en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/rheumatology/kep402en_HK
dc.identifier.pmid20026564en_HK
dc.identifier.scopuseid_2-s2.0-77950534152en_HK
dc.identifier.hkuros234991-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77950534152&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume49en_HK
dc.identifier.issue3en_HK
dc.identifier.spage520en_HK
dc.identifier.epage527en_HK
dc.identifier.isiWOS:000274487000016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMok, MY=7006024184en_HK
dc.identifier.scopusauthoridHuang, FP=55238926300en_HK
dc.identifier.scopusauthoridIp, WK=36999273200en_HK
dc.identifier.scopusauthoridLo, Y=35148230000en_HK
dc.identifier.scopusauthoridWong, FY=36999602700en_HK
dc.identifier.scopusauthoridChan, EYT=7401994013en_HK
dc.identifier.scopusauthoridLam, KF=8948421200en_HK
dc.identifier.scopusauthoridXu, D=7404073685en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats